Conference Paper
RDF
pages:
-
A phase I study of systemic sorafenib in combination with isolated limb infusion with melphalan (ILI-M) in patients (pts) with locally advanced in-transit melanoma
-
A phase I study of the safety and activation of a cathepsin-activatable fluorescent cancer-specific probe LUM015.
-
A phase I study to determine the safety and pharmacokinetics of intravenous administration of SB715992 on a once weekly for three consecutive weeks schedule in patients with refractory solid tumors
-
A phase I trial of a multi-epitope cancer vaccine (EP-2101) in non-small cell lung (NSCLC) and colon cancer patients.
-
A phase I trial of AP23573, a novel mTOR inhibitor, in patients (Pts) with recurrent malignant glioma.
-
A phase I trial of gefitinib (ZD1 839) plus rapamycin for patients with recurrent malignant glioma.
-
A phase I trial of imatinib (GLEEVEC), hydroxyurea and RAD001 for patients with recurrent malignant glioma
-
A phase I trial of imatinib, hydroxyurea and RAD001 for patients with recurrent malignant glioma.
-
A PHASE I TRIAL OF MK-0752 IN PEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY CNS MALIGNANCIES: A PEDIATRIC BRAIN TUMOR CONSORTIUM STUDY
-
A phase I trial of scutellaria barbata (BZL101) for metastatic breast cancer
-
A Phase I, First-in-Human Study Evaluating the Safety and Preliminary Antileukemia Activity of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Other CD123-Positive Hematologic Malignancies
-
A phase I, open label, perioperative study of AG-120 and AG-881 in recurrent IDH1 mutant, low-grade glioma: Results from cohort 1.
-
A Phase I, Open-Label Study to Evaluate the Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity of PF-06863135, a B-Cell Maturation Antigen/CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Advanced Multiple Myeloma
-
A Phase I-II Study of the Combination of Bendamustine and Pomalidomide with Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma.
-
A PHASE I/II STUDY OF ADOPTIVE T-CELL THERAPY (ALT) AND DC VACCINATION (DCV) DURING RECOVERY FROM MYELOABLATIVE CHEMOTHERAPY AND HEMATOPOIETIC STEM CELL TRANSPLANTATION (HDC plus ASCR) OR NON-MYELOABLATIVE CONDITIONING (NMA) IN PATIENTS (PTS) WITH RECURRENT CENTRAL PNETS (RE-MATCH PROTOCOL)
-
A Phase I/II Study of Capecitabine (Cape), Oxaliplatin (Ox), Panitumumab (Pmab), and External Beam Radiation Therapy (RT) for Patients With Esophagogastric Carcinoma (EC)
-
A phase I/II study of capecitabine (Cape), oxaliplatin (Ox), panitumumab (Pmab), and external beam radiation therapy (RT) for patients with esophagogastric carcinoma (EC).
-
A phase I/II study of LDE225, a smoothened (Smo) antagonist, in pediatric patients with recurrent medulloblastoma (MB) or other solid tumors.
-
A Phase I/II Study of Neoadjuvant Liposomal Doxorubicin, Paclitaxel and Hyperthermia in Locally Advanced Breast Cancer
-
A phase I/II study of preoperative oxaliplatin (0), 5-fluorouracil (5-FU), and external beam radiation therapy (XRT) in locally advanced rectal cancer: CALGB 89901.
-
A phase I/II study of systemic ADH-1 in combination with isolated limb infusion with melphalan (ILI-M) in patients (pts) with locally advanced in-transit melanoma
-
A PHASE I/II STUDY OF VORINOSTAT PLUS DAILY TEMOZOLOMIDE AND BEVACIZUMAB IN THE TREATMENT OF PATIENTS WITH RECURRENT MALIGNANT GLIOMA
-
A phase I/II trial of cabozantinib (C) with or without panitumumab (P) in patients (pts) with RAS wild-type (WT) metastatic colorectal cancer (mCRC): Clinical outcomes in pts with MET
amplification (amp) detected in blood.
-
A phase Ia study of safety and clinical activity of atezolizumab (atezo) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
-
A phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) in combination with pazopanib in patients with advanced soft tissue sarcoma (STS)
-
A phase Ib study of abemaciclib with therapies for metastatic breast cancer.
-
A phase Ib/II study of cancer stemness inhibitor napabucasin (BB608) combined with weekly paclitaxel in advanced non-small cell lung cancer.
-
A Phase II Prospective Feasibility Study of Clofarabine Cytoreduction Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) for Patients with Relapsed or Refractory Acute Leukemias and Advanced Myelodysplastic Syndromes
-
A PHASE II PROSPECTIVE STUDY OF SELUMETINIB IN CHILDREN WITH RECURRENT OR REFRACTORY LOW-GRADE GLIOMA (LGG): A PEDIATRIC BRAIN TUMOR CONSORTIUM (PBTC) STUDY
-
A phase II prospective study of selumetinib in children with recurrent or refractory low-grade glioma (LGG): A Pediatric Brain Tumor Consortium (PBTC) study.
pages: